Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir
Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir
复制标题
DOI：
10.1001/archderm.133.8.987
复制
发表时间：
1997-08-01
影响因子：
--
通讯作者：
Rallis, TM
中科院分区：
文献类型：
--
作者：
Meadows, KP;Tyring, SK;Rallis, TM
背景资料：传染性软疣病毒（Ivf CV）引起皮肤生长，主要影响儿童，性活跃的成年人和免疫功能低下的个体。人类免疫缺陷病毒感染患者的MCV病变可以是大的和众多的，和可用的治疗反应往往是unsatisfactory.Observations：我们描述了3名男子感染人类免疫缺陷病毒谁提出了广泛的MCV病变，是没有反应的各种治疗。患者I在开始静脉内西多福韦治疗他的治疗抗性双侧CMV视网膜炎时，并且由于西多福韦对MCV的可能活性，他的MCV病变显示出戏剧性的清除。在病例2中，将西多福韦作为3%乳膏在组合载体（Dermovan）中混合用于广泛的面部受累，并且在治疗1个月后观察到MCV完全消退。在病例3中，开始静脉注射西多福韦治疗CMV视网膜炎，并试图清除90%的面部MCV受累;治疗1个月后，MCV的所有临床证据均已消退。所有3例患者仍然明确recursion.Conclusions：西多福韦，脱氧胞苷一磷酸的核苷酸类似物，似乎有助于清除先进的MCV病变，在这3例患者，从而提供了提示性的证据，对MCV的临床活性。西多福韦治疗人类免疫缺陷病毒感染者MCV的对照试验是必要的。
Background: Molluscum contagiosum virus (Ivf CV) causes cutaneous skin growths that mainly affect children, sexually active adults, and immunocompromised individuals. Lesions of MCV in patients infected with human immunodeficiency virus can be large and numerous, and response to available treatments is often unsatisfactory.Observations: We describe 3 men infected with human immunodeficiency virus who presented with extensive MCV lesions that were not responsive to various treatments. Patient I demonstrated dramatic clearing of his MCV lesions when intravenous cidofovir therapy was started for his treatment-resistant bilateral CMV retinitis and because of cidofovir's possible activity against MCV. In case 2, cidofovir was compounded as a 3% cream in a combination vehicle (Dermovan) for extensive facial involvement, and complete resolution of MCV was seen after 1 month of therapy. In case 3, intravenous cidofovir therapy was started both for CMV retinitis and in an attempt to clear 90% facial MCV involvement; after I month of treatment, all clinical evidence of MCV had resolved. All 3 patients remain clear of recurrence.Conclusions: Cidofovir, a nucleotide analog of deoxycytidine monophosphate, appears to have contributed to clearing of advanced MCV lesions in these 3 patients, thus providing suggestive evidence of clinical activity against MCV. Controlled trials of cidofovir therapy for MCV in persons infected with human immunodeficiency virus are warranted.